ABSTRACTSince the emergence of CoVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In Vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule) of an Iodine-complex (Renessans). A monolayer of vero cells were exposed to SARS-CoV-2 in the presence and absence of different concentrations (equivalent to 50, 05 and 0.5 μg/ml of I2) of Renessans. Anti-SARS-CoV-2 activity of each of the formulation was assessed in the form of cell survival, SARS-CoV-2-specific cytopathic effect (CPE) and genome quantization. With varying concentrations of syrup and capsule, a varying rate of inhibition of CPE, cells survival and virus replication was observed. Compared to 0.5 μg/ml concentration of Renessans syrup, 5 and 50 μg/ml showed comparable results where there was a 100% cell survival, no CPEs and a negligible viral replication (ΔCT= 0.11 and 0.13, respectively). This study indicates that Renessans, containing iodine, may have potential activity against SARS-CoV-2 which needs to be further investigated in human clinical trials.

In this work, a validated finite element-based coupled optical, thermal, and electrical model is used to assess the performance of a dual concentrated photovoltaic system thermally regulated using a phase change material for the environmental conditions of Lahore, Pakistan. Thermal management of the system is achieved using a selected PCM; that has a melting temperature of 53-56?C, a thermal conductivity of 19 W/m K, and heat of fusion of 220 kJ/kg. Thermal regulation and power output of the system are analyzed for a clear day of six months of a year. It is found that the maximum temperature of the upper photovoltaic cell is ~80?C while for the bottom photovoltaic cell is ~82?C in July. The percentage power gain obtained after the addition of an upper concentrated photovoltaic cell is ~17.9 %. The maximum and minimum power of the system is found to be 0.079 kWh/day/m 2and 0.041 kWh/day/m2 in May and November respectively.

No abstract